In the present study, we demonstrated that STIL expression was significantly associated with tumor immune infiltrations and promising immunotherapy targets (such as PD-L1, CTLA-4, and TIM3), indicating that targeting STIL might increase the efficacy of immunotherapy in HCC. The gene discussed is CTLA4; the disease is neoplasm.